換組蛋白質療法

融合蛋白質及其他的療法

1月9日∼10日

藉由組合創意和生物學產生之換組蛋白質療法，是與迄今可提高生物學療法的安全性和效果不同的新「設計」。此部會針對抗體以外生物醫藥品應留意的世界，介紹已獲得認可的產品和現在屬於臨床開發階段的產品等各種治療用融合蛋白質。此外，亦預定舉行由業界的意見領袖介紹特異性構造體和免疫原性未解決課題中已達成的重要進步之研習會。

實現融合蛋白療法的可能性

OPENING KEYNOTE PRESENTATION:

George Yancopoulos, Executive Vice President, CSO & President, Regeneron Pharmaceuticals, Inc.

FEATURED PRESENTATION:
Therapeutic Fusion Proteins and Their Modular Components: From Albumin to XL-Protein

Stefan Schmidt, Ph.D., M.B.A., CSO, ERBiotech

蛋白質間相互作用的標的化

Targeting Protein-Protein Interactions with Engineered Cyclotides

Julio Camarero, Ph.D., Associate Professor, Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles

Protein-Fragment Complementation and Semi-Rational Design: Engineering Specific Antagonists of Protein-Protein Interactions

Jody M. Mason, Ph.D., Senior Lecturer, Biochemistry, University of Essex

克服各種課題之治療法設計的革新

XTENylation Enables Monthly Dosing of Biopharmaceuticals

Volker Schellenberger, Ph.D., Vice President, Drug Discovery, Amunix

From Clinical Imaging to Serum Half-Life Extension of Affibody Molecules & Biopharmaceuticals

Joachim Feldwisch, Ph.D., Director, Preclinical Development, Affibody AB

多功能性的開發

Multifunctional Fusion Proteins Based on Engineered Antibody Domains

Dimiter Dimitrov, Ph.D., Head, Protein Interaction Group; Senior Investigator, Center for Cancer Research, NCI-Frederick, NIH

Multifunctional Nanolipoprotein Particles using Telodendrimer Chemistry for Immunomodulation

Matthew Coleman, Ph.D., Associate Adjunct Professor, Radiation Oncology, University of California, Davis; Senior Scientist, Biology and Biotechnology, Lawrence Livermore National Laboratory

Trivalent Atrimers Therapeutics: A New Grasp on Receptors for Potent Protein Therapeutics

Anke Kretz-Rommel, Ph.D., Vice President, Research & Development, Anaphore, Inc.

開發與疾病作戰的技術

Engineered Receptor Tyrosine Kinase Domains for Treatment of Metastatic Cancers

Jennifer Cochran, Ph.D., Assistant Professor, Bioengineering, Stanford University

融合蛋白質技術

Kunitz Domain Fusion Proteins for in vitro Screening and in vivo Analysis

Andrew Nixon, Ph.D., Vice President, Lead Discovery & Biochemistry, Discovery Research, Dyax Corp.